Dr Reddys Laboratories (RDY) Operating Income Growth (3y) (2012 - 2026)
Analysis
Dr Reddys Laboratories (RDY) Operating Income Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.72 Bn | 39.07 Bn | 2.15 Bn | 29.31% |
| 2 | Viatris | 19.14 Bn | 18.26 Bn | 1.46 Bn | -74.25% |
| 3 | Dr Reddys Laboratories | 9.89 Bn | 9.71 Bn | 396.53 Mn | -42.93% |
| 4 | Amneal Pharmaceuticals | 5.46 Bn | 5.34 Bn | 334.51 Mn | 17.46% |
| 5 | Bausch Health Companies | 2.33 Bn | 494.50 Mn | 2.10 Bn | 21.56% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 48.31% |
| 8 | Amphastar Pharmaceuticals | 994.43 Mn | 704.31 Mn | 93.47 Mn | 2.50% |
| 9 | Fennec Pharmaceuticals | 399.34 Mn | 358.09 Mn | 17.15 Mn | 33.37% |
| 10 | RedHill Biopharma | 178.33 Mn | 178.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.93% |
| Mar 31, 2026 | -59.11% |
| Dec 31, 2025 | 1.92% |
| Sep 30, 2025 | 0.13% |
| Jun 30, 2025 | 8.84% |
| Mar 31, 2025 | 116.07% |
| Dec 31, 2024 | 43.52% |
| Sep 30, 2024 | 19.76% |
| Jun 30, 2024 | 9.65% |
| Mar 31, 2024 | 26.49% |
| Dec 31, 2023 | 25.87% |
| Sep 30, 2023 | 93.14% |
| Jun 30, 2023 | 23.55% |
| Mar 31, 2023 | 24.45% |
| Dec 31, 2022 | 19.72% |
| Sep 30, 2022 | 65.88% |
| Jun 30, 2022 | 15.42% |
| Mar 31, 2022 | -35.64% |
| Dec 31, 2021 | -0.87% |
| Sep 30, 2021 | 13.70% |